Literature DB >> 7913118

Influence of interleukin-1 on neutrophil function and resistance to Streptococcus suis in neonatal pigs.

J Shi1, R D Goodband, M M Chengappa, J L Nelssen, M D Tokach, D S McVey, F Blecha.   

Abstract

Nonspecific immunity is usually lower in neonates than adults. Consequently, enhancing the neonate's nonspecific immune capability may be beneficial for the health and growth performance of young animals. We conducted two experiments in which neonatal pigs were injected with recombinant bovine interleukin-1 beta (rBoIL-1 beta) at 9 to 11 days of age. Three consecutive daily injections of rBoIL-1 beta increased neutrophil and monocyte numbers, which remained elevated until the animals were challenged with Streptococcus suis at 19 days of age. Neutrophil bactericidal activity was greater in interleukin-1-treated pigs than in saline-injected controls. At lower ratios of effector to target cells, neutrophil-mediated, antibody-dependent cellular cytotoxicity was increased in neonates treated with IL-1. However, natural killer cell activity and neutrophil production of superoxide anion were not affected by treatment with IL-1. Expression of CD18 was increased transiently on neutrophils from IL-1-treated pigs at 15 days of age. Severity of the streptococcal infection was less in pigs that were treated with IL-1 at 9 to 11 days of age. These data suggest that IL-1 treatment in neonates may augment nonspecific immune function and disease resistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913118     DOI: 10.1002/jlb.56.1.88

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  9 in total

1.  PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox.

Authors:  J Shi; C R Ross; T L Leto; F Blecha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Recombinant bovine interleukin-1beta amplifies the effects of partially purified Pasteurella haemolytica leukotoxin on bovine neutrophils in a beta(2)-integrin-dependent manner.

Authors:  F Leite; J F Brown; M J Sylte; R E Briggs; C J Czuprynski
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide.

Authors:  J Shi; C R Ross; M M Chengappa; M J Sylte; D S McVey; F Blecha
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Salmonella infection increases porcine antibacterial peptide concentrations in serum.

Authors:  G Zhang; C R Ross; S S Dritz; J C Nietfeld; F Blecha
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

5.  TREM-1 signaling promotes host defense during the early stage of infection with highly pathogenic Streptococcus suis.

Authors:  Chao Yang; Bo Chen; Jianqing Zhao; Lan Lin; Li Han; Shan Pan; Lei Fu; Meilin Jin; Huanchun Chen; Anding Zhang
Journal:  Infect Immun       Date:  2015-06-08       Impact factor: 3.441

Review 6.  Streptococcus suis: past and present.

Authors:  J J Staats; I Feder; O Okwumabua; M M Chengappa
Journal:  Vet Res Commun       Date:  1997-08       Impact factor: 2.459

7.  Cutting Edge: IL-1α and Not IL-1β Drives IL-1R1-Dependent Neonatal Murine Sepsis Lethality.

Authors:  John T Benjamin; Daniel J Moore; Clayton Bennett; Riet van der Meer; Ashley Royce; Ryan Loveland; James L Wynn
Journal:  J Immunol       Date:  2018-10-10       Impact factor: 5.422

8.  The role of protegrins and other elastase-activated polypeptides in the bactericidal properties of porcine inflammatory fluids.

Authors:  J Shi; T Ganz
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

Review 9.  Triggering Receptor Expressed on Myeloid Cells-1 Signaling: Protective and Pathogenic Roles on Streptococcal Toxic-Shock-Like Syndrome Caused by Streptococcus suis.

Authors:  Li Han; Lei Fu; Yongbo Peng; Anding Zhang
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.